E valuation of new coronary devices and demonstration of their conformity to essential principles of safety and effectiveness requires clinical trials in human subjects. Today, many trials designed to address device-oriented safety and effectiveness rely on quantitative coronary angiographic lesion severity, as an objective reproducible end point to determine whether revascularization for progressive luminal renarrowing after device therapy is clinically indicated. Given the known limitations of angiography to reflect clinical ischemia, concern exists regarding the applicability of such angiographic end points. An invasive objective functional (physiological) assessment of moderate stenoses by coronary pressure-derived fractional flow reserve has evident potential as an adjunct to quantitative coronary angiography in clinical trials. To be implemented as a potential core laboratory technique, standardization in technique and archiving of permanent data storage are imperative. The intent of this report is to propose standards for fractional flow reserve data acquisition and interpretation in coronary device research.
E valuation of new coronary devices and demonstration of their conformity to essential principles of safety and effectiveness requires clinical trials in human subjects. Today, many trials designed to address device-oriented safety and effectiveness rely on quantitative coronary angiographic lesion severity, as an objective reproducible end point to determine whether revascularization for progressive luminal renarrowing after device therapy is clinically indicated. Given the known limitations of angiography to reflect clinical ischemia, concern exists regarding the applicability of such angiographic end points. An invasive objective functional (physiological) assessment of moderate stenoses by coronary pressure-derived fractional flow reserve has evident potential as an adjunct to quantitative coronary angiography in clinical trials. To be implemented as a potential core laboratory technique, standardization in technique and archiving of permanent data storage are imperative. The intent of this report is to propose standards for fractional flow reserve data acquisition and interpretation in coronary device research.
Controlled trials with predefined safety and efficacy end points are a critical element in the assessment of new therapies or devices, for approval by regulatory bodies, and subsequent adoption for clinical use by the medical community. It is important that randomized trials adopt meaningful clinical end points that relate to the pathophysiological mechanism(s) most likely responsible for the clinical outcome. [1] [2] [3] In coronary device investigations, clinically driven repeat revascularization of the target lesion is a key (deviceoriented) outcome measure of clinical effectiveness. 1 Adju-dication of this end point has been based on the presence of clinical symptoms and angiographic lesion severity as determined by a central core laboratory using quantitative coronary angiography (QCA), such that even moderate stenosis (Ͼ50% diameter stenosis) by QCA may be considered clinically significant. Most clinical trial designs do not require functional assessment prior to repeat revascularization.
The coronary pressure-derived fractional flow reserve (FFR) index provides a valuable tool to assess the justification for coronary revascularization in patients that have a moderate to severe coronary lesion. 1 The coronary pressurederived FFR index is a well-validated, accurate, and objective index for assessing lesion-specific physiological stenosis severity and a surrogate marker of long-term outcome in various clinical conditions and anatomic subsets. 4 -26 To be implemented as a potential core laboratory technique (eg, in coronary stent investigations), standard procedures for data acquisition and storage are essential prerequisites. Accuracy, elimination of technical or operator-related artifacts, and reproducibility of FFR measurements are critical. The aim of this report is to propose a standard methodology for FFR data acquisition and to highlight potential pitfalls in data interpretation. We will also propose guidelines for how FFR may be incorporated into clinical trial designs. Detailed reviews of coronary physiology and the fundamentals of FFR are available elsewhere. [27] [28] [29] 
Specific Requirements for Core Laboratory Analysis
Routine measurement of FFR in the cardiac catheterization laboratory involves standard catheters (diagnostic or guiding), a dedicated pressure wire, drugs used during coronary intervention (vasodilator and anticoagulant), and a pharmacological stimulus to produce maximal hyperemia. For research purposes, standardization is warranted. Technical or operator-related artifacts should be identified and avoided.
Catheters
Although the use of diagnostic catheters is technically feasible, guiding catheters without distal side holes are a prerequisite for research measurements. Guiding catheters facilitate manipulation of the pressure wire. Furthermore, immediate intervention can be performed where indicated (including the rare event of vessel injury by the wire).
Pressure Wire
There are 2 commercially available pressure wires. Both systems [the Pressure Wire (RadiMedical Systems Inc, Upp-sala, Sweden) and the Volcano Wave Wire (Volcano Inc, Rancho Cordova, CA)] measure intracoronary pressure using a dedicated solid-state (electronic) sensor mounted on a 0.014-inch (0.33-mm) floppy-tipped guide wire. The sensor is located at the junction between the 3-cm-long radiopaque tip of the wire and the nonradiopaque section of the wire. The cross-sectional area of a sensor guide wire is negligible relative to all but the most critical stenoses. 12
Pharmacologically Induced Maximal Hyperemia
Hyperemia is essential for stenosis assessment. Maximal vasodilatation of the 2 compartments of the coronary circulation (epicardial or "conductance arteries Ͼ400 m" and the microvasculature or "resistance arteries") is required for accurate and reproducible measurements.
To abolish epicardial vasoconstrictor tone, an intracoronary bolus of 2 mg of isosorbide dinitrate or an equivalent dose of another nitrate such as nitroglycerin (200 g) should be administered at least 2 minutes before FFR measurement. To obtain maximum microvascular vasodilation and eliminate coronary autoregulation, a continuous infusion of adenosine through a large-bore cannula, in a large vein, at a rate of 140 g/kg per minute, is recommended. It provides steady-state maximum hyperemia within 2 minutes. Continuous adenosine infusion is advocated because it allows for FFR measurement in specific settings (ie, at aorta-coronary ostial lesions) and permits recording of a pressure pullback curve to differentiate focal from diffuse coronary artery disease. The injection of additional intracoronary boluses of adenosine, in an attempt to stimulate maximal hyperemia, is discouraged because it may provoke artifacts in the FFR tracing due to the injection that complicate off-line analysis. Similarly, other vasodilators such as papaverine and sodium nitroprusside, administered as boluses, are not advocated due to the transient steady state achieved.
Pressure Measurement
For clinical research purposes, a uniform systematic and 5-step-by-step FFR procedure is proposed.
Step 1: Zero the Pressure System to the Atmosphere A standard fluid-filled pressure transducer is used for aortic pressure recordings. Special attention should be paid to purging the system of air, zeroing of the catheter tubing system, and obtaining an optimal aortic pressure waveform. The guiding catheter should be frequently flushed with normal saline (at least every 10 minutes). Because contrast medium may subtly dampen the catheter pressure waveform, all contrast medium should be flushed from the catheter during the zeroing steps before pressure measurement. If any pressure damping or ventricularization of the catheter pressure waveform is observed, the guiding catheter should be gently disengaged from the ostium, taking care not to alter the position of the pressure wire in the distal vessel.
Zero the sensor of the pressure wire ex vivo, following the instructions of the manufacturer.
Step 2: Insert the Pressure Sensor Guide Wire Into the Guide and Equalize the 2 Pressures In Vivo
The sensor of the pressure wire should be advanced a few millimeters beyond the tip of the guiding catheter. For aorto-ostial lesions, this should be performed with the disengaged catheter in the ascending aorta. Then, equalize the pressures registered by the guiding catheter and the pressure wire. The introducer needle can remain in the Y connector during equalization and measurement of FFR when intravenous adenosine is used to induce maximal hyperemia.
Step 3: Advance the Pressure Wire Sensor Distal to the Region of Interest
The sensor should be advanced to the distal two-thirds part of the coronary artery and at least 2 to 3 cm distal to the index lesion and its final position documented angiographically. Ensure that the wire tip is rotating freely and no resistance is felt when torque is applied.
Step 4: Induce Maximal Hyperemia
When the sensor has been optimally positioned distal to the stenotic region, administer adenosine 140 g/kg per minute intravenously for at least 2 minutes for calculation of the FFR. FFR is then calculated as the ratio of distal coronary pressure (Pd) to aortic pressure (Pa) at maximal hyperemia, the nadir of (Pd).
If needed, a pullback curve should be performed to determine the exact location of the lesion most likely responsible for ischemia. The pressure pullback curve may demonstrate either a single (or several) abrupt change(s) in FFR across focal narrowing(s) or a gradual change in the presence of diffuse disease without focal obstructions. Before pullback curves are performed, an angiogram should be obtained and the position of the image intensifier should not change subsequently. When appropriate, insert "bookmarks" to indicate areas where abrupt changes occur and use the "store fluoroscopy" function to document these sites to facilitate off-line, Core Laboratory, analysis.
Step 5: Wire Pullback to Check for Signal Drift Verification of equal pressure signals from the pressure wire and the guiding catheter must be documented at the end of the procedure to check for potential drift. 13 Where the difference is minimal (Ͻ5 mm Hg), this difference should be taken into account in the calculation of the final FFR. Where the difference is Ͼ5 mm Hg, the last measurement must be repeated.
All measurements should be stored on an external medium (eg, hard disc) for core laboratory review.
Pitfalls and Artifacts of FFR Measurement

Instrumentation Issues
Care must be taken to avoid potential impairment to coronary flow during maximum hyperemia. This is most commonly induced by the presence of the guiding catheter in the coronary artery and can be detected by observing a change in the morphology of the aortic pressure curve (ie, damping or ventricularization) (Figure) . When this occurs, it is important to disengage the guiding catheter from the ostium during the measurement while continuing the adenosine infusion. On occasion, particularly in tortuous vessels, the presence of the wire may create multiple "pseudostenoses" and render FFR measurements uninterpretable. 28, 30, 31 
Pressure Signal Drift Versus True Pressure Gradient
With currently available electronic sensor-tipped pressure guide wires, temporal drift is minimal. Drift (a resetting of the baseline pressure signal) can be detected by assessing the pressure curve (dicrotic notch, pressure curve morphology) and by comparing the pressure recorded by the wire to the pressure recorded at the guiding catheter at the end of the procedure (should be Ͻ5 mm Hg/h) (Figure) . In the case of drift, the sensor should be pulled back to the tip of the guiding catheter to equalize pressures again. The measures should then be repeated. 30, 31 
Influence of the Guide Wire Across the Lesion on Stenosis Hemodynamics
For lesions of intermediate angiographic severity, the crosssectional area of the 0.014-inch guide wire is Ͻ10% of the minimal lumen area, and FFR should provide a true gradient that reliably reflects epicardial resistance. 3
Data Collection and Interpretation
In clinical research, the clinical event adjudication process should be highly specific, accurate, and consistent and mainly driven by the application of prespecified criteria for event definitions applied within a specific scenario.
FFR is reproducible and reaches per-segment accuracy with a spatial resolution of a few millimeters. FFR is specific and provides well-defined cutoff values that distinguish normal from abnormal levels for a given measurement with a narrow "gray zone" between 0.75 and 0.80 (up to 10% of all measurements), the use of which requires clinical judgment. Because the latter may introduce a factor of variability in Figure. Pitfalls and artifacts of fractional flow reserve (FFR) measurement. All panels shows simultaneous aortic pressure (Pa) and distal coronary pressure (Pd) recordings during steady-state maximal hyperemia as induced by an intravenous infusion of adenosine. A, Example of the impact of catheter ventricularization/ damping on the accuracy of FFR measurement. Disengaging the guiding catheter from the coronary artery ostium may prove critical in cases where the lesion under evaluation is "borderline." B, Example of pressure signal drift (as compared with a true pressure gradient). Pressure signal drift should be suspected in the case of parallel pressure signals (similar morphology for Pa and Pd signal) throughout diastole and systole. The aortic dicrotic notch is preserved (Pd pressure signal) despite a large pressure difference. C, Example of a pressure pullback tracing in a diffusely diseased left anterior descending coronary artery under steady-state maximal adenosine intravenously induced hyperemia. The distal pressure increases progressively in 4 or 5 "steps." This indicates that the abnormal FFR value is due to diffuse disease rather than to 1 focal lesion. D, Example FFR in a tortuous right coronary artery with the development of pseudostenosis (uninterpretable FFRЈ). judgment, for research purposes the single cutoff value of 0.80 is proposed. It should be recognized that the nonischemic threshold of FFR (Ͻ0.75) was derived from a selected, stable patient population with single-vessel coronary disease and normal left ventricular function.
We advocate the use of FFR as a marker of hemodynamically significant luminal renarrowing associated with moderate-to-severe stenosis within the stented segment or other discrete lesions elsewhere in the target vessel (Table) . Its use to justify target lesion revascularization is discouraged 
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in patients with diffuse coronary atherosclerosis and serial focal lesions or extensive coronary atherosclerosis on angiography and a graded, continuous pressure fall along the arterial length. The data are limited for patients with acute or recent myocardial infarction, and the proposed criteria should not currently be extended to this specific patient subgroup. 10, 21 
Incorporating FFR Into Clinical Trial Designs
We propose that FFR assessment be incorporated into clinical trial designs as a criterion for determination of clinical significance of moderate-to-severe angiographic lesions. Our focus is on the use of FFR for justification of repeat revascularization procedures as a part of clinical end point adjudication, but its value at the time of study entry should also be considered. There are several requirements for standardization and quality assurance of data measurement and interpretation.
Establish a Central Core Laboratory
A central laboratory should be selected that is charged with training and review of sample data from prospective clinical centers. The core laboratory should review recorded data from study procedures to validate accuracy and make a central determination of FFR, based on the recorded data.
Quality Assurance of FFR Measures
Each clinical center should be trained in the 5-step procedure as outlined herein. Study data capture methods should document the steps in the procedure. Sample cases should be reviewed by the core laboratory before study subject entry. Any concerns with data ascertainment or interpretation detected by the core laboratory should be provided by immediate feedback to the clinical center.
Trial Design Issues
The most important trial design concern with incorporating FFR data into the end point adjudication process will be the assurance of uniform ascertainment. The protocol must specify clearly which suspected lesions should undergo FFR assessment. We propose that all moderate-to-severe lesions, determined to be 50% to 80% by visual estimate, should undergo FFR measurement unless there are both typical ischemic symptoms and another functional study showing evidence of ischemia in the target vessel territory. The study protocol and clinical events committee manual of operations must also clearly outline, in advance, how FFR data will be incorporated into the adjudication process in specific scenarios. Examples are cases in which the percent diameter stenosis is assessed as moderate (50% to 70%) by QCA and FFR is not performed before repeat revascularization or cases in which there is discordance between the FFR result and the results of prior noninvasive testing. We recommend that where protocol-mandated FFR is not performed, a worst-case scenario should be adopted, and that where FFR results differ from the results of noninvasive testing, FFR should take precedence in the decision-making hierarchy.
Conclusion
Invasive coronary physiological studies have demonstrated favorable outcomes for decision-making in patients with intermediate single-vessel stenosis and have evident potential as an adjunct to QCA in the setting of clinical trials. Based on the value of FFR in terms of objective and clinically relevant information, we support its incorporation into clinical studies to establish standardized reporting of specific device-related angiographic and clinical events.
Table. Fractional Flow Reserve in Coronary Device Trials
FFR may be used to guide patient inclusion in coronary device trials, to select patients with moderate-to-severe coronary lesions who will benefit from coronary revascularization.
FFR may be considered as marker of coronary device performance failure and clinical justification for repeat revascularization in coronary device trials.
In patients with isolated coronary stenosis of moderate severity (Ͼ50% diameter stenosis determined by an independent quantitative coronary angiographic core laboratory or visual assessment), including isolated left main coronary artery renarrowing, and assessment of jailed side branch lesions.
FFR should not be considered as a marker of coronary device failure in:
Patients with diffuse coronary atherosclerosis with a Ͻ50% diameter luminal renarrowing at angiography and a graded, continuous fall along the arterial length.
Patients with serial stenoses within 1 coronary artery.
FFR indicates fractional flow reserve.
